Aeva Technologies CFO disposes 160K shares at $13.00–$13.61 range
Rhea-AI Filing Summary
Aeva Technologies CFO Saurabh Sinha reported the sale of 160,000 shares of the issuer's common stock on 08/18/2025 at a weighted average price of $13.3328 per share, with individual trade prices ranging from $13.00 to $13.61. After the reported disposition, the reporting person beneficially owns 810,710 shares, held directly. The Form 4 indicates the transaction was not part of an amendment and was filed by one reporting person.
The filing includes an explanatory note that the reporting person will provide details on the number of shares sold at each separate price within the stated range to the issuer or SEC staff upon request.
Positive
- Timely and complete disclosure of an insider sale with signature and explanatory note about trade prices
- Clear remaining ownership shown: 810,710 shares beneficially owned following the transaction
Negative
- Insider disposition of 160,000 shares could be viewed unfavorably by some investors, though no reason is provided
Insights
TL;DR: The company's CFO sold 160,000 shares at a weighted average of $13.3328, leaving 810,710 shares owned; this is a routine insider sale.
The sale is clearly disclosed with a price range of $13.00 to $13.61 and an undertaking to provide per-trade detail if requested. The filing is a standard Section 16 Form 4 showing a single-day disposition by an officer. There is no mention of derivative transactions or changes to indirect ownership. Based solely on this filing, the event is a disclosed insider sale rather than a corporate operational change.
TL;DR: Insider compliance appears intact: timely Form 4, signature present, and explanatory note on trade pricing provided.
The document shows the reporting person certified the filing with a signature dated 08/18/2025 and included the required explanatory statement about weighted average pricing and availability of detailed trade information. The filing identifies the reporting person as CFO and confirms direct beneficial ownership after the sale. No amendments, contracts, or derivative instruments are disclosed in this Form 4.